MPCUK

Professor Sarah Danson is a Consultant Medical Oncologist specialising in melanoma and lung cancer treatments. She was an Undergraduate in Medicine at Nottingham University and then undertook Speciality Medical Oncology training, including a PhD in Clinical Pharmacology, at the Christie Hospital, Manchester. Sarah moved to Sheffield in 2006 and now leads the Sheffield ECMC (Experimental Cancer Medicine Centre) assessing novel drugs and treatment strategies in cancer. She was recently appointed as NIHR National Speciality for Cancer: Early Phase Trials. Sarah has extensive experience in the use of immunotherapy and is the Chief Investigator for the DANTE trial assessing treatment duration with PD1 inhibitors.